FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a method for creating a cell model of leukaemia for modelling and studying processes occurring in leukaemia cells. Method is aimed at detecting those single cells in the population in which translocation has occurred, and their selection. Primary selection is carried out by fluorescence of the reporter protein, and ensuring that all elements (Cas9 and RNA guide genes) required for translocation induction have entered the cell is ensured by the fact that all these elements together with the fluorescent protein gene are assembled into one plasmid. Such a plasmid for inducing a new translocation is created on the basis of a universal vector in two cloning steps. To detect translocation, PCR is used, and without a separate step of DNA extraction (so-called direct PCR), combining this approach with embedded PCR, which increases sensitivity of the method. For reliable production of a cell line with a translocation with a probability of not less than 0.95, a preliminary check of the effectiveness of RNA guides and counting the frequency of translocations can be carried out. Based on the frequency of translocations, an optimal cloning strategy into subpopulations and a strategy of PCR analysis with combining several samples into one reaction are selected. Cloning is carried out using a cell sorter. Obtained monoclonal lines are characterized for the presence of translocation, the rearrangement region is sequenced, the expression of the fused gene product is shown and can be further used for the declared purposes.
EFFECT: invention enables to obtain monoclonal lines with translocations in the shortest possible time and with minimal time and laboratory resources.
21 cl, 5 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
TEST SYSTEM FOR SEARCHING FOR DRUGS WHICH REDUCE THE RISK OF SECONDARY LEUKEMIA, A METHOD FOR PREPARING AND USING IT | 2018 |
|
RU2720475C2 |
CELL LINE AND METHOD OF EVALUATING EFFICIENCY OF GENOME EDITORS | 2022 |
|
RU2831064C2 |
RECOMBINANT PLASMID DNA LENTI sgRNA(MS2)_zeo_Myc, PROVIDING ACTIVATION OF Myc GENE EXPRESSION IN HUMAN CELLS, METHOD OF OBTAINING HUMAN CELLS WITH STABLY INCREASED EXPRESSION OF Myc GENE AND MONOCLONAL HUMAN BREAST CANCER CELL LINE BT549_Myc WITH STABLY INCREASED EXPRESSION OF Myc GENE | 2022 |
|
RU2812975C1 |
METHOD OF PRODUCING GENETICALLY MODIFIED RABBITS WITH LEPR GENE KNOCKOUT USING CRISPR/Cas9 SYSTEM | 2023 |
|
RU2836438C1 |
RECOMBINANT PLASMID DNA pSNCA-C-3XFLAG-2XST-DONOR PROVIDING STABLE DOXYCYCLINE-DRIVEN EXPRESSION OF ALPHA-SYNUCLEIN CHIMERIC PROTEIN IN HUMAN CELL CULTURES | 2022 |
|
RU2795156C1 |
NUCLEIC ACID FOR ALLOTOPIC EXPRESSION OF MT-ND4 GENE | 2023 |
|
RU2809065C1 |
MINI-PROTEIN USH2A, NUCLEIC ACID CODING MINI-PROTEIN USH2A, AND EXPRESSION VECTOR FOR GENE THERAPY CONTAINING SAME | 2023 |
|
RU2822884C1 |
METHOD OF PRODUCING MOUSE MODEL FOR STUDYING DUCHENNE MUSCULAR DYSTROPHY AND VERSIONS OF ITS THERAPY | 2023 |
|
RU2815936C1 |
METHOD OF OBTAINING RECOMBINANT VESICULAR STOMATITIS VIRUS | 2022 |
|
RU2807751C1 |
UNIVERSAL INTEGRATION VECTOR SB7G_HIGH AND RECOMBINANT PLASMID SB7G_HIGH_DEV_57, PROVIDING SYNTHESIS AND SECRETION OF RECOMBINANT HUMAN ANTIBODY TO RECEPTOR-BINDING DOMAIN (RBD) OF CORONAVIRUS SARS-CoV-2 IN MAMMALIAN CELLS AND OBTAINED USING UNIVERSAL VECTOR SB7G_HIGH, AND RECOMBINANT MONOCLONAL ANTIBODY DEV_K57, HAVING VIRUS-NEUTRALIZING ACTIVITY ON SARS-CoV-2 | 2023 |
|
RU2829359C1 |
Authors
Dates
2024-10-03—Published
2023-12-30—Filed